

Appendix 1. Studies of angiotensin receptor blockers and risk of cancer, included in 3 published meta-analyses and current re-analyses, listed in alphabetical order (part 1 of 2)

Study Identifier	Reference
ACTIVE-I	ACTIVE I Investigators; Yusuf F, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, et al. Irbesartan in patients with atrial fibrillation. <i>N Engl J Med</i> 2011;364(10):928-938.
ALPINE	Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). <i>J Hypertens</i> 2003;21(8):1563-1574.
CHARM	Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet</i> 2003;362(9386):759-766.
DIRECT	Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. <i>Lancet</i> 2008;372(9647):1394-1402.
GISSI-AF	GISSI-AF Investigators; Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. <i>N Engl J Med</i> 2009;360(16):1606-1617. Erratum in: <i>N Engl J Med</i> 2009;360(22):2379.
HIJ-CREATE	Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, et al.; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). <i>Eur Heart J</i> 2009;30(10):1203-1212.
IDNT	Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al.; Irbesartan Diabetic Nephropathy Trial Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. <i>Ann Intern Med</i> 2003;138(7):542-549.
I-PRESERVE	Zile MR, Gaasch WH, Anand IS, Haas M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation</i> 2010;121(12):1393-1405.
IRMA-2	Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.] <i>Ugeskr Laeger</i> 2001;163(40):5519-5524. Danish.
JIKEI	Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al, for the Jikei Heart Study / group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. <i>Lancet</i> 2007;369(9571):1431-1439.
KYOTO Heart Study	Sawada T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. <i>Eur Heart J</i> 2009;30(20):2461-2469.
LIFE	Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet</i> 2002;359(9311): 995-1003.
NAVIGATOR	The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauser B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>N Engl J Med</i> 2010;362(16):1477-1490.
ONTARGET	ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med</i> 2008;358(15):1547-1559.

continued on page E11

Supplementary material for Egan G, Lee J, Minhas R, Tejani AM. Does outcome reporting bias “cause” cancer? Risks associated with hidden data on angiotensin receptor blockers. *Can J Hosp Pharm* 2012;65(5):387-393.

Appendix 1. Studies of angiotensin receptor blockers and risk of cancer, included in 3 published meta-analyses and current re-analyses, listed in alphabetical order (part 2 of 2)

Study Identifier	Reference
PROFESS	Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al.; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. <i>N Engl J Med</i> 2008;359(12):1225-1237.
RENAAL	Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>N Engl J Med</i> 2001;345(12):861-869.
SCOPE	Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. <i>J Hypertens</i> 2003;21(5):875-886.
Suzuki et al.	Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. <i>Am J Kidney Dis</i> 2008;52(3):501-506.
TRANSCEND	Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. <i>Lancet</i> 2008;372(9644):1174-1183.
TROPHY	Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al.; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. <i>N Engl J Med</i> 2006;354(16):1685-1697.
Val-HeFT	Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. <i>N Engl J Med</i> 2001;345(23):1667-1675.
VALIANT	Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Engl J Med</i> 2003;349(20):1893-1906.
VALUE	Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet</i> 2004;363(9426):2022-2031.

Supplementary material for Egan G, Lee J, Minhas R, Tejani AM. Does outcome reporting bias “cause” cancer? Risks associated with hidden data on angiotensin receptor blockers. *Can J Hosp Pharm* 2012;65(5):387-393.